Candel Therapeutics
Tracked across 1 events · 9 articles · First seen Feb 19, 2026 · Last active Feb 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Candel Therapeutics announced the pricing of a public offering of its common stock, expecting to raise $100 million. This capital will be used to fund the launch of aglatimagene besadenovec for prostate cancer, ongoing development costs for its phase 3 trial in non-small cell lung cancer, and general corporate purposes. This offering is expected to provide significant capital for the company's operations and product development.
Feb 19, 2026 · 9 articles
Arcadia Securities
co-manager
↔
Candel Therapeutics
Brookline Capital Markets, a division of Arcadia Securities, is a co-manager for
Stifel
joint bookrunning manager
↔
Candel Therapeutics
Stifel is a joint bookrunning manager for Candel Therapeutics' public offering.
LifeSci Capital
lead manager
↔
Candel Therapeutics
LifeSci Capital is the lead manager for Candel Therapeutics' public offering.
NEWSDESK
Track Candel Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard